EULAR系统性硬化症疾病影响(ScleroID)问卷在弥漫性系统性硬化症患者中作为患者报告结局测量工具的性能
在152例弥漫性系统性硬化症(dcSSc)患者中评估EULAR ScleroID问卷的性能,与SSc-HAQ、EQ-5D和SF-36比较。ScleroID结构效度良好(与SSc-HAQ的Spearman相关系数0.79),内部一致性高(Cronbach's alpha 0.87),重测信度优(ICC 0.89),对变化敏感性中等但优于对照工具,支持将其作为dcSSc随机对照试验中的PROM。
要点
- ScleroID在dcSSc中结构效度良好,与SSc-HAQ的Spearman相关系数为0.79(95%CI 0.69-0.86)。
- ScleroID内部一致性高(Cronbach's alpha 0.87),重测信度优(ICC 0.89,95%CI 0.84-0.92)。
- ScleroID对变化敏感性中等(改善亚组SRM -0.63,恶化亚组SRM 0.48),但优于对照工具。
核心结论
- EULAR ScleroID在dcSSc患者中表现良好,支持将其作为PROM纳入随机对照试验并定期评估。
研究设计与样本
- 纳入大型多中心ScleroID队列中所有dcSSc患者,共分析152例(29%男性,中位年龄54岁)。
- 以SSc-HAQ、EuroQol-5 Dimensions和36项简表健康调查(SF-36)作为对照工具。
- 研究包含纵向臂,设7±3天可靠性访视和12个月随访访视。
- 依据风湿病学结局测量(OMERACT)过滤器评估ScleroID在dcSSc中的性能。
主要发现
- ScleroID与SSc-HAQ的Spearman相关系数为0.79(95%CI 0.69-0.86),与HAQ残疾指数为0.72(95%CI 0.60-0.80),与SF-36生理评分为-0.69(95%CI -0.77至-0.60)。
- 内部一致性强(Cronbach's alpha 0.87,分半信度系数0.88)。
- 纵向臂中44例完成可靠性访视,113例完成随访访视,其中19/113(17%)报告显著变化(11例改善,8例恶化)。
- 重测信度优(组内相关系数0.89,95%CI 0.84-0.92),对变化敏感性中等(改善亚组标准化反应均数-0.63,恶化亚组0.48),但优于对照工具。
关键数值与推荐
- 结构效度:与SSc-HAQ的Spearman相关系数0.79(95%CI 0.69-0.86)。
- 内部一致性:Cronbach's alpha 0.87,分半信度系数0.88。
- 重测信度:组内相关系数0.89(95%CI 0.84-0.92)。
- 敏感性:改善亚组标准化反应均数-0.63,恶化亚组0.48。
临床怎么用
- 原文结论支持将EULAR ScleroID作为PROM纳入dcSSc随机对照试验并定期评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic sclerosis Impact of Disease (ScleroID) is the first comprehensive patient-reported outcome measure (PROM) specifically developed for systemic sclerosis (SSc). We investigated the performance of ScleroID in patients with diffuse cutaneous SSc (dcSSc), as a prerequisite for its use in randomised controlled trials (RCTs) testing potentially disease-modifying drugs. METHODS: All patients with dcSSc from the large, multicentric, ScleroID cohort were included. SSc-Health Assessment Questionnaire (HAQ), EuroQol-5 Dimensions and 36-item Short Form Health Survey (SF-36) were used as comparators. The study includes a longitudinal arm with a reliability visit at 7±3 days and a 12 months follow-up visit. The performance of ScleroID in dcSSc was assessed according to the Outcome Measures in Rheumatology filter. RESULTS: In total, 152 dcSSc patients were analysed (29% male, median age 54 years). ScleroID reflected well the disease impact of dcSSc, showing a good construct validity with high Spearman's correlation coefficients with comparators (SSc-HAQ, 0.79, 95% CI (0.69, 0.86); HAQ-Disability Index, 0.72 95% CI (0.60, 0.80); SF-36 physical score, -0.69 95% CI (-0.77, -0.60)). The internal consistency was strong (Cronbach's alpha 0.87, split-half reliability coefficient 0.88).In the longitudinal arm, 44 patients had a reliability visit and 113 had a follow-up visit, of whom 19/113 (17%) reported a significant change (11 improved, 8 worsened). ScleroID showed a good consistency and discriminative ability with excellent test-retest reliability (intraclass correlation coefficient 0.89, 95% CI (0.84, 0.92)) and moderate sensitivity to change (standardised response mean -0.63 in the improved subgroup and 0.48 in the worsened subgroup), but superior to the comparators. CONCLUSION: The European Alliance of Associations for Rheumatology (EULAR) ScleroID performs well for patients with dcSSc. This supports its inclusion and regular assessment as PROM in RCTs.
引用
- Dobrota R, Garaiman A, Fligelstone K, et al. Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis. RMD Open. 2024. PMID: 39608865. doi:10.1136/rmdopen-2024-004653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。